



المشاريع البحثية المدعومة خلال العام الجامعي 2024/2023		
أ.د. بلال عمر النجار Prof. Dr. Belal Omar Al-Najjar		الباحث الرئيسي
 Dr. Moath Helal (Al-Najah University – Palestine) Dr. Fadi Ghassan Saqallah (Al-Zaytoonah University - Jordan) Prof. Dr. Brian John BANDY (University of Saskatchewan - Canada) 	 د. معاذ هلال (جامعة النجاح – فلسطين) د. فادي غسان سقا الله (جامعة الزيتونة – الأردن) أ.د. براين جون باندي (جامعة ساسكاتشوان – كندا) 	الباحثين المشاركين
ا كلية الصيـــدلة / الصيدلة (قسم العلوم الصيدلانية)		الكلية/
Faculty of Pharmacy / Pharmacy (Pharmaceutical Sciences Department)		التخصص





π النمذجة الجزيئية والاختبارات المخبرية نحو تصميم مثبطات انتقائية لأنزيم جلوتاثيون أس-ترانسفيريز نوع Molecular modeling and In-Vitro assay toward Designing selective GSTπ inhibitors	اسم المشروع البحثي
1. استخدام نماذج الخواص الدوانية، والربط الجزيئي ونهج تحليل QSAR للتمييز بين الأنواع الفرعية المختلفة لأنزيم جلوتاثيون أسـترانسفيريز نوع المتخدام هذه النماذج كمرشح فحص افتراضي لفحص قواحد بيانات كبيرة مثل قواحد بيانات المخبرية. 5. فهم آلية الارتباط باستخدام تقنية محاكاة الديناميكيات الجزيئية. 6. Use combined pharmacophore models, molecular docking and QSAR analysis approach to differentiate between the different GST subtypes. 7. Employ the approaches as a screening filter to virtually screen large database such as NCI and Maybridge databases. 8. Select, evaluate, and characterize the compounds that have the highest selectivity and binding affinity towards GSTπ. 8. Evaluate the selective cytotoxicity for the GSTπ of the selected compounds via in-silico and in-vitro methods. 9. Understand the mechanism of Binding using Molecular Dynamics simulation technique. 10. Study the Pharmacokinetic properties of the lead compounds using In-Silico tools.	اهداف المشروع





تم قبول دعم المشروع البحثي في The research project has been approved for funding on March 31, 2024 The research project has been approved for funding on March 31, 2024 The research project has been approved for funding on March 31, 2024 A salidation of the project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding on March 31, 2024 The project has been approved for funding been approved to the project has been approved to the project has been approved to the project has been approved to carcinogenesis, tumor formation, and drug approaches. Alterations in mitochondrial physiology within cancer cells have shown promise. Targeting cellular and mitochondrial thiols, including GST enzymes, is of great interest. Among GSTs, cGSTs are complex and disease-linked. GSTπ, prominent in tumor cells and mitochondria, contributes to carcinogenesis, tumor formation, and drug resistance. GSTμ and GSTα are typically found in normal cells. Thus, selectively targeting GSTπ offers potential for cancer cell-specific cytotoxicity, holding promise for improved therapies. Emphasizing the critical role of GSTπ selectivity could revolutionize cancer treatment paradigms. Achieving targeted cytotoxic effects while sparing normal cells would mark a significant advancement.	حالة المشروع ملخص عن عن المشروع
Prof. Brian Bandy profile: https://pharmacy-nutrition.usask.ca/profiles/brian-bandy.php University of Saskatchewan QS Ranking: https://www.topuniversities.com/universities/university-saskatchewan	روابط مهمت





